Sage Therapeutics (SAGE) Stock Forecast & Price Target

$5.10 -0.27 (-5.03%)

(As of 11/15/2024 ET)

Sage Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 21 Analyst Ratings

Sell
2

Hold
17

Buy
2

Based on 21 Wall Street analysts who have issued ratings for Sage Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 2 have given a sell rating, 17 have given a hold rating, and 2 have given a buy rating for SAGE.

Consensus Price Target

$12.89
152.72% Upside

According to the 21 analysts' twelve-month price targets for Sage Therapeutics, the average price target is $12.89. The highest price target for SAGE is $26.00, while the lowest price target for SAGE is $4.00. The average price target represents a forecasted upside of 152.72% from the current price of $5.10.

SAGE Analyst Ratings Over Time

Type	Current Forecast 11/17/23 to 11/16/24	1 Month Ago 10/18/23 to 10/17/24	3 Months Ago 8/19/23 to 8/18/24	1 Year Ago 11/17/22 to 11/17/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	3 Buy rating(s)
Hold	17 Hold rating(s)	17 Hold rating(s)	16 Hold rating(s)	15 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$12.89	$13.76	$16.06	$43.78
Forecasted Upside	152.72% Upside	90.91% Upside	97.28% Upside	128.49% Upside
Consensus Rating	Hold	Reduce	Reduce	Hold

Let’s be blunt (Ad)

Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Check out the $100 Challenge now

SAGE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SAGE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sage Therapeutics Stock vs. The Competition

Type	Sage Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	152.72% Upside	28,534.17% Upside	9.92% Upside
News Sentiment Rating	Positive News See Recent SAGE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/30/2024	Scotiabank 5 of 5 stars		Lower Target	Sector Outperform ➝ Sector Outperform	$17.00 ➝ $14.00	+118.75%
10/30/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$52.00 ➝ $26.00	+281.23%
10/30/2024	Oppenheimer 3 of 5 stars		Lower Target	Market Perform ➝ Market Perform	$9.00 ➝ $8.00	+17.65%
10/30/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$13.00 ➝ $8.00	+16.79%
10/30/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$25.00 ➝ $14.00	+79.72%
10/30/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
Urgent: This election is rigged (Ad) If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now.
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underperform ➝ Underperform	$11.00 ➝ $6.00	-10.58%
10/9/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$9.00 ➝ $8.00	+19.23%
10/9/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$13.00 ➝ $9.00	+39.97%
10/4/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$10.00 ➝ $4.00	-42.78%
8/6/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$12.00 ➝ $10.00	+15.21%
7/30/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Baral Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$16.00 ➝ $10.00	-7.49%
7/26/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$19.00 ➝ $11.00	+1.95%
7/19/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$18.00 ➝ $16.00	+31.47%
5/29/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/29/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sell	$8.00	-32.94%
4/26/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$21.00 ➝ $17.00	+25.18%
2/28/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $22.00	+0.09%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$22.00 ➝ $20.00	-6.41%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$21.00	+4.90%
8/7/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$311.00 ➝ $294.00	+1,655.22%
5/3/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
1/3/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:31 AM ET.

SAGE Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Sage Therapeutics is $12.89, with a high forecast of $26.00 and a low forecast of $4.00.
: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 2 sell ratings, 17 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
: According to analysts, Sage Therapeutics's stock has a predicted upside of 152.72% based on their 12-month stock forecasts.
: Over the previous 90 days, Sage Therapeutics's stock had 1 downgrade by analysts.
: Sage Therapeutics has been rated by research analysts at Bank of America, HC Wainwright, Needham & Company LLC, Oppenheimer, Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Scotiabank, Truist Financial, and Wedbush in the past 90 days.
: Analysts like Sage Therapeutics less than other "medical" companies. The consensus rating for Sage Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SAGE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The pin that pops the AI bubble (Ad)

My new documentary explores the background to this pattern and how and why I believe it will almost certainly repeat itself with the AI frenzy. I urge you to watch it before you invest another cent. Again, to be clear, I’m no Chicken Little. Far from it.

So go here now to read my new report The Big AI Die-Up… while you still can.

This page (NASDAQ:SAGE) was last updated on 11/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sage Therapeutics (SAGE) Stock Forecast & Price Target